Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Nicolas Alejandro Fraunhoffer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1561-2563; OpenAlex author ID A5045888426. Sources: OpenAlex.

Their work

Papers
30 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
72
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 6 papers · 2022: 3 papers · 2023: 4 papers · 2024: 3 papers · 2025: 5 papers · 2026: 7 papers

Papers 30

  1. Decoding the Integrated Stress Response of Pancreatic Cancer: Identifying a Serine-dependent Tumor Subset Under Metabolic Relationships With CAFs. Co-author DOI 10.1002/advs.202515740↗
  2. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Co-author DOI 10.1016/j.isci.2026.115164↗
  3. Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102920↗
  4. Single-cell transcriptomic profiling of patient-derived pancreatic ductal adenocarcinoma primary cell cultures. Last author DOI 10.1038/s41597-026-07380-3↗
  5. A comprehensive proteomic dataset of secretomes from primary pancreatic cancer cell cultures. Co-author DOI 10.1038/s41597-026-07902-z↗
  6. Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. Co-author DOI 10.1200/jco-26-00327↗
  7. Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline r… Co-author DOI 10.64898/2026.09.07.749857↗
  8. Toward Precision Chemotherapy for Pancreatic Cancer Guided by Transcriptomic Signatures. Co-author DOI 10.1002/ueg2.70124↗
  9. Reply to the Letter to the Editor 'AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma' by Y. Shimazu. Co-author DOI 10.1016/j.annonc.2024.09.016↗
  10. KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102421↗
  11. Understanding the heterogeneity of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.tranon.2025.102479↗
  12. The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma. First author DOI 10.1093/oncolo/oyaf083↗
  13. Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.annonc.2024.06.010↗
  14. Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer. Co-author DOI 10.3389/fonc.2024.1437200↗
  15. The xenobiotic transporter ABCC4/MRP4 promotes epithelial mesenchymal transition in pancreatic cancer. Co-author DOI 10.3389/fphar.2024.1432851↗
  16. Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells. Co-author DOI 10.1016/j.ebiom.2023.104602↗
  17. Pancreatic ductal adenocarcinoma ubiquitination profiling reveals specific prognostic and theranostic markers. First author DOI 10.1016/j.ebiom.2023.104634↗
  18. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2022.11.035↗
  19. [The mRNA vaccine for the treatment of pancreatic cancer is here to stay]. Co-author PMID 37582144↗
  20. Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. Co-author DOI 10.1002/cac2.12335↗
  21. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Co-author DOI 10.1002/cac2.12365↗
  22. Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction. Co-author DOI 10.1038/s41698-022-00299-z↗
  23. Targeting REG3β limits pancreatic ductal adenocarcinoma progression through CTGF downregulation. Co-author DOI 10.1016/j.canlet.2021.08.024↗
  24. Metabolomic profiling of pancreatic adenocarcinoma reveals key features driving clinical outcome and drug resistance. First author DOI 10.1016/j.ebiom.2021.103332↗
  25. Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. Co-author DOI 10.1016/j.ejca.2021.06.038↗
  26. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. First author DOI 10.3390/cancers13102473↗
  27. Induction of Apoptosis in Human Pancreatic Cancer Stem Cells by the Endoplasmic Reticulum-Targeted Alkylphospholipid Analog Edelfosine and Potentiation by Auto… Co-author DOI 10.3390/cancers13236124↗
  28. DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study. Co-author DOI 10.3390/cancers13246354↗
  29. Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib. Co-author DOI 10.1158/1078-0432.ccr-20-1232↗
  30. Dissecting the Anticancer Mechanism of Trifluoperazine on Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11121869↗

Closest collaborators

The 25 strongest of 72 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nelson Dusetti · 27 shared papers, 2020–2026 · strength 5.60
  2. Juan Iovanna · 28 shared papers, 2019–2026 · strength 5.53
  3. Brice Chanez · 9 shared papers, 2022–2026 · strength 2.03
  4. Julie Roques · 9 shared papers, 2020–2026 · strength 1.65
  5. Analía Meilerman Abuelafia · 10 shared papers, 2019–2026 · strength 1.64
  6. Odile Gayet · 9 shared papers, 2020–2026 · strength 1.36
  7. Eduardo Chuluyán · 8 shared papers, 2020–2026 · strength 1.35
  8. Rémy Nicolle · 8 shared papers, 2021–2026 · strength 1.24
  9. Raul A. Urrutia · 5 shared papers, 2021–2025 · strength 1.05
  10. Pascal R. Hammel · 4 shared papers, 2024–2026 · strength 0.92
  11. Philippe Soubeyran · 4 shared papers, 2021–2026 · strength 0.86
  12. Daniel Grasso · 4 shared papers, 2023–2026 · strength 0.81
  13. Agustín Yaneff · 4 shared papers, 2023–2026 · strength 0.76
  14. Jonathan Garnier · 3 shared papers, 2026 · strength 0.69
  15. Gwen Alyce Lomberk · 4 shared papers, 2021–2025 · strength 0.68
  16. Patricia Santofimia‐Castaño · 4 shared papers, 2019–2025 · strength 0.61
  17. Oscar Mazza · 3 shared papers, 2023–2026 · strength 0.57
  18. María Eugenia Pasqualini · 3 shared papers, 2023–2026 · strength 0.57
  19. María Noé Garcia · 3 shared papers, 2023–2026 · strength 0.57
  20. Daniela Laura Papademetrio · 3 shared papers, 2023–2026 · strength 0.57
  21. Ana Sahores · 3 shared papers, 2023–2026 · strength 0.54
  22. Cindy Neuzillet · 2 shared papers, 2025–2026 · strength 0.51
  23. Emmanuel Mitry · 3 shared papers, 2023–2026 · strength 0.49
  24. Jerome F. Cros · 3 shared papers, 2021–2026 · strength 0.47
  25. Flora Poizat · 2 shared papers, 2023–2026 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.